The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization
Pieter Martens1, Matthias Dupont1, Jeroen Dauw1
1Department of Cardiology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, Genk 3600, Belgium.
Iron deficiency treatment with ferric carboxymaltose (FCM) significantly improved cardiac function in heart failure with reduced ejection fraction (HFrEF) patients. This intervention led to enhanced left ventricular ejection fraction (LVEF) and improved cardiac contractility.
Area of Science:
- Cardiology
- Cardiovascular Medicine
- Pharmacology
Background:
- Iron deficiency is prevalent in heart failure with reduced ejection fraction (HFrEF), negatively impacting cardiac function and structure.
- Cardiac resynchronization therapy (CRT) is a treatment for HFrEF, but some patients remain symptomatic with reduced ejection fraction.
Purpose of the Study:
- To investigate the effect of ferric carboxymaltose (FCM) on cardiac reverse remodeling and contractile status in HFrEF patients with iron deficiency.
- To assess if FCM can improve left ventricular ejection fraction (LVEF) and cardiac performance in HFrEF patients post-CRT.
Main Methods:
- A prospective, double-blind, randomized study involving symptomatic HFrEF patients with iron deficiency and LVEF <45% at least 6 months post-CRT.
- Patients were randomized to receive either FCM or standard of care (SOC).
- Primary endpoint was the change in LVEF at 3-month follow-up; secondary endpoints included changes in left ventricular volumes and the force-frequency relationship.
Main Results:
- The FCM group showed a significantly greater increase in LVEF (+4.22%) compared to the SOC group (-0.23%) after 3 months (P < 0.001).
- Left ventricular end-systolic volume (LVESV) significantly improved in the FCM group, indicating reverse remodeling.
- FCM treatment improved the cardiac force-frequency relationship, suggesting enhanced cardiac contractility, and led to better functional status and exercise capacity.
Conclusions:
- Ferric carboxymaltose (FCM) treatment in HFrEF patients with iron deficiency and persistent low LVEF post-CRT leads to significant improvements in cardiac function.
- Key improvements include increased LVEF, reduced LVESV, and enhanced cardiac contractility as evidenced by the force-frequency relationship.
- FCM is a viable therapeutic option for improving cardiac remodeling and function in this patient population.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
09:16Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Heart Failure Drugs: Inotropic Agents
